Treat the first patient with MT-401 manufactured in the new cGMP facility
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 13 Jan 2021
- Due
- 30 Jun 2021
- Checked
- 24 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Company expects to complete tech transfer and treat first patient with MT-401 manufactured in new cGMP facility in H1 2021”
What we found
Evidence strength A What the grades mean
The company did not begin manufacturing MT-401 at its new cGMP facility until the fourth quarter of 2021, missing the first-half 2021 deadline for treating a patient with product from that facility.
-
A Marker Therapeutics, Inc. 10-Q filed 2021-11-10
“We expect to begin manufacturing MT-401 for the Phase 2 trial at our cGMP manufacturing facility in the fourth quarter of 2021” ✓ confirmed on the page
-
A Marker Therapeutics, Inc. 10-K filed 2022-03-17
“we began manufacturing MT-401 for our Phase 2 trial in AML in the fourth quarter of 2021.” ✓ confirmed on the page
Market reaction: the shares moved -5.3% against the S&P 500 over the three sessions around the disclosure (9 Nov 2021 to 12 Nov 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Treat
- Deliverable
- First patient treated with MT-401
- Where
- Houston, TX
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: receiving regulatory approval for the cGMP manufacture
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Marker Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-MRKR-021975 · Corrections policy